Article
In vivo and molecular docking studies of the pathological mechanism underlying adriamycin cardiotoxicity
28 Mar 2023
Abstract excerpt
Adriamycin (ADR), one of the most effective broad-spectrum antitumor chemotherapeutic agents in clinical practice, is used to treat solid tumors as well as hematological malignancies in adults and children. However, long-term ADR use causes several adverse reactions, including time- and dose-dependent cardiotoxicity, which limit its clinical application. In addition, the mechanism by which ADR induces...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
